If you are experiencing side effects that make you reluctant to continue treatment , such as persistent nausea, vomiting, or gastrointestinal discomfort, discuss these openly with your healthcare provider rather than simply missing doses
The NEXAPH formulation is prepared under internal quality procedures to ensure that each vial meets strict standards for consistency and purity
Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties
Neither peptide has been through human clinical trials as a therapeutic agent all the safety data is preclinical
If your main goal is to lose weight, injectable semaglutide, particularly Wegovy, is likely your best bet
The peptide strength protocol benefits article explores these synergies in detail